Navigation Links
Viagra May Shield Heart From Blood Pressure Damage
Date:1/5/2009

Sildenafil appears to delay dangerous heart muscle expansion in mice

MONDAY, Jan. 5 (HealthDay News) -- Tests in mouse hearts show that sildenafil, the key ingredient in Viagra, may shield hearts from damage caused by high blood pressure, a new study suggests.

Investigators said that sildenafil appears to influence RGS2, a single protein essential in the reactions that initially protect the heart's blood-pumping function from spiraling into heart failure. The findings, published online Monday in The Journal of Clinical Investigation, suggest that sildenafil may prove useful in the treatment or prevention of heart damage due to chronic high blood pressure.

"Sildenafil clearly prolongs the protective effects of RGS2 in mouse hearts," senior investigator Dr. David Kass, a cardiologist and professor of medicine at the Johns Hopkins University School of Medicine and its Heart and Vascular Institute in Baltimore, said in a Hopkins news release.

After a week of inducing high blood pressure in the mice, the team found that the hearts engineered to lack RGS2, or regulator of G-protein signaling 2, expanded in weight by 90 percent, and almost half of the experiment animals died of heart failure. In the mice with RGS2, the dangerous muscle expansion, known as hypertrophy, was delayed, growing by only 30 percent, the researchers found, and none of those mice died.

Later testing showed that treating hypertensive mice that had RGS2 with sildenafil showed enhanced buffering, less hypertrophy, and stronger heart muscle contraction and relaxation. In addition, these mice showed as much as 10 times lower stress-related enzyme activity compared to their untreated counterparts. The study also found that sildenafil had no effect in mice lacking RGS2.

The study involved more than a half-dozen experiments, all performed within the last three years, designed to zero in on RGS2's role in stalling hypertrophy.

"The evidence is piling up that unbridled Gq signaling is driving a central biological chain reaction in heart failure, and that by extending the protective effects of RGS2 or by developing a test for its presence, researchers can develop new therapies or improve existing ones, including ACE inhibitors and possibly sildenafil, for people with heart failure who will benefit most," Kass said.

Doctors currently use so-called ACE inhibitor and ARB inhibitor drugs to block Gq signaling. These drugs are the most common treatment for heart failure, which afflicts more than 5 million Americans each year, killing more than a quarter million of them, according to the study.

More information

For more on the symptoms of heart failure, go to American Heart Association.



-- HealthDay staff



SOURCE: Johns Hopkins University School of Medicine, news release, Jan. 2, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Viagra Bulk Effectively Cures Children with PAH (Pulmonary Arterial Hypertension)
2. For Patients Who Fail on Viagra, Levitra or Cialis
3. Viagra May Protect Hearts of Some Muscular Dystrophy Patients
4. TriMix-gel vs Viagra, Levitra, Cialis Data to Be Presented at AUA
5. AUDIO from Medialink and Pfizer: Viagras 10th Anniversary
6. An Important Message to Anyone Taking Viagra ... From The Women Who Love You ... and Zoller Labs
7. Blue Cross and Blue Shield of Florida Launches Cover Florida Plans for the Uninsured
8. Blue Cross and Blue Shield of Florida Completes Acquisition of Florida Health Care Plans
9. Blue Cross and Blue Shield of Oklahoma Announces Autism Benefits
10. Study Shows Exercise Shields Against Osteoporosis
11. Drug Shields Mice From Emphysema
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Viagra May Shield Heart From Blood Pressure Damage
(Date:7/26/2017)... ... 26, 2017 , ... Evergreen Healthcare Partners is proud to ... to provide innovative offerings to their healthcare partners. These solutions will help Evergreen’s ... teams to address healthcare IT’s biggest challenges. , “Adding Talent Management Solutions to ...
(Date:7/26/2017)... ... July 26, 2017 , ... The ... Process Validation and Process Validation Statistics Conferences in Bethesda, Maryland, 12 – ... challenges faced by process validation professionals and statisticians today. , “These conferences ...
(Date:7/26/2017)... , ... July 26, 2017 , ... “We are thrilled ... the ability for patients to schedule an appointment online in real time,” said Keith ... Six Month Smiles provider directory will bring more Six Month Smiles patients to their ...
(Date:7/26/2017)... ... July 26, 2017 , ... The Amnesty Rally 2017 will be held on ... 3313 Bernstein Park Drive in Monroe (adjacent to the Louisiana Purchase Gardens & Zoo). ... gun violence throughout Monroe. Citizens can turn in unregistered, illegally-held and imitation guns to ...
(Date:7/25/2017)... ... , ... “Now Hiring!” is a popular phrase at Home Delivery Incontinent ... sales for over 30 consecutive years and now plans to hire more than 100 ... excitement and growth at HDIS, following the company’s acquisition by Fortune 1000 company Domtar. ...
Breaking Medicine News(10 mins):
(Date:7/24/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO ... quarter 2017 operating results on Monday, August 7, 2017 ... at 5:00 p.m. ET. ... live broadcast of the conference call by dialing 877-201-0168 ... 51641230 approximately 15 minutes prior to the call. A ...
(Date:7/21/2017)... 21, 2017 Did you know that PhRMA member companies ... that combined spending on brand medicines, generics and the supply chain ... accounting for just half of this (7 percent)? Or that ... the world,s venture capital investments in high-growth biopharmaceutical startups? ... ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
Breaking Medicine Technology: